Background Tuberculosis (TB) and hepatitis viruses infection are the two common co-infections in patients infected with human immunodeficiency virus (HIV). Hepatitis B and Hepatitis C infections are common in Sudan where TB is endemic and HIV is prevalent. Since anti-retroviral drugs and some of the anti- TB drugs are hepatotoxic, in HIV/TB co-infected patients, the management may be difficult, thus early detection of these viruses will influence the outcome of the disease. The objective of this study to determine the Seroprevalence of Hepatitis B (HBs Ag) and Hepatitis C (Anti-HCV) viruses among Sudanese patients with HIV/TB co-infection Methodology From November 2014 to March 2015 , a cross-sectional hospital based study was conducted among HIV/TB co infected patients attended at a reference centers in Khartoum State ,Sudan .The participants were tested for serological markers of HBC infection and HBV antibodies. Sera samples were collected from patients and tested for HBsAg and anti- HCV bodies using Enzyme-Linked ImmunoSorbent Assay (ELISA). Results Out of 53 HIV/ TB co-infected patients recruited in the study, HBsAg was detected in 9.4% while anti HCV antibodies was detected in 1.9% of patients using ELISA and there was no patient had both HBV and HCV co- infection. Conclusion HIV/TB infected patients have high probability of getting HBV and or HCV infection due to enhanced immunodeficiency by HIV. Shared route of transmission also plays significant role and is of epidemiological importance in our country .Thus routine screening of HIV/TB infected patients for concurrent infection with HBV and HCV should be made mandatory because co-infection with these hepatitis viruses will increase the risk of cirrhosis, liver deficiency and mortalities in comparison to when a person is infected with HIV and this may minimize the risk of hepatotoxicity occurring during treatment of such patient.